Eosinophilic Esophagitis: Experts Address Your Burning Questions

Overview

Provider Statement

This continuing education activity is provided by 

Support Statement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc., and Sanofi.

Activity Description

Eosinophilic esophagitis (EoE) is a chronic type 2 helper (Th2)-mediated inflammatory disorder that is characterized by symptoms of esophageal dysfunction and esophageal inflammation with intraepithelial eosinophils. Once considered rare, EoE is a relatively new disease that is now commonplace and affects both children and adults. When left unmanaged, EoE can impact a patient’s ability to eat properly, leading to food impaction and increased medical expenses. Recent data indicate that many clinicians are unaware of the optimal treatment of EoE, including best practices for the differential diagnosis and treatment selection for these patients. This was reflected in the questions submitted by the audience at a symposium on the topic of EoE at a recent gastroenterology society meeting. In this educational podcast series, expert faculty discuss these questions to provide practical guidance for the management of EoE in real-world practice.

Target Audience

The intended audience for this activity is gastroenterologists and other healthcare professionals involved in the management of patients with eosinophilic esophagitis (EoE).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Outline diagnostic criteria and modalities for the detection of eosinophilic esophagitis (EoE) for adult and pediatric patients.
• Assess the clinical evidence for current, newly approved, and emerging therapies in the management of EoE.

Activity Chair

Evan S. Dellon, MD, MPH
Professor
Division of Gastroenterology and Hepatology
Department of Medicine
University of North Carolina School of Medicine
Chapel Hill, NC

Faculty

Claire Beveridge, MD
Associate Staff
Department of Gastroenterology, Hepatology & Nutrition
Cleveland Clinic
Assistant Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, OH

Mirna Chehade, MD, MPH
Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, NY

Ikuo Hirano, MD, FACG
Professor of Medicine
Division of Gastroenterology and Hepatology
Northwestern University Feinberg School of Medicine
Chicago, IL

Planner/Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Accreditation

In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, May 31, 2023, to May 30, 2024.

How to Participate in This Activity and Obtain CE Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, listen to the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 6 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Activity Chair and Faculty report the following relevant financial relationship(s)

Claire Beveridge, MD
Consultant: Lucid Diagnostics

Mirna Chehade, MD, MPH
Consultant: Adare/Ellodi, Allakos, AstraZeneca, Bristol Myers Squibb, Phathom, Recludix Pharma, Regeneron, Sanofi, Shire/Takeda
Independent Research Contractor: Adare/Ellodi, Allakos, AstraZeneca, Danone, Regeneron, Shire/Takeda

Evan S. Dellon, MD, MPH
Consultant: Abbott, AbbVie, Adare/Ellodi, Aimmune, Akeso, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, EsoCap, Eupraxia, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, Lilly, Lucid Diagnostics, Nexstone, Nutricia, Parexel/Calyx, Phanthom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE
Independent Research Contractor: Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celgene/Receptos/Bristol Myers Squibb, GSK, Meritage, Miraca Life Science, Nutrica, Regeneron, Revolo, Shire/Takeda
Educational Grants: Allakos, Holoclara, Invea

Ikuo Hirano, MD, FACG
Consultant: Allakos, AstraZeneca, Bristol Myers Squibb/Celgene, Calyx/Parexel, Dermavant, Ellodi/Adare, EsoCap, Nexstone, Pfizer/Arena, Phathom, Sanofi/Regeneron, Takeda/Shire
Speaker Contracted by Ineligible Company: Sanofi/Regeneron
Independent Research Contractor: Allakos, Arena, AstraZeneca, Bristol Myers Squibb/Celgene, Ellodi/Adare, Regeneron, Takeda/Shire

Planner/Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this web activity is available upon request. Requests should include the web activity title and emailed to cme@vindicoCME.com. Requests will be honored within 3 to 5 business days.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at cme@vindicoCME.com